PepGen Appoints New CEO, Dr. Michael Yaszemski

TL;DR

PepGen has a new CEO, Dr. Michael Yaszemski, effective Sept 16th. Dr. Rose out, Dr. Deitcher in as CMO.

AI Summary

PepGen Inc. announced on September 19, 2024, that its Board of Directors has appointed Dr. Michael J. Yaszemski as Chief Executive Officer and a member of the Board, effective September 16, 2024. Dr. Yaszemski, who previously served as Chief Medical Officer, will succeed Dr. James R. Rose. The company also announced the appointment of Dr. Steven M. Deitcher as Chief Medical Officer.

Why It Matters

A change in CEO can signal a shift in company strategy or operational focus, potentially impacting its stock performance and future development pipeline.

Risk Assessment

Risk Level: medium — CEO changes can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Players & Entities

• PepGen Inc. (company) — The company filing the report.
• Michael J. Yaszemski (person) — Newly appointed Chief Executive Officer and Board member.
• September 16, 2024 (date) — Effective date of the new CEO's appointment.
• James R. Rose (person) — Outgoing Chief Executive Officer.
• Steven M. Deitcher (person) — Newly appointed Chief Medical Officer.
• September 19, 2024 (date) — Date of the report.

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share PEPG Nasdaq Global Select

Filing Documents

• pepg-20240919.htm (8-K) — 40KB
• pepg-ex99_1.htm (EX-99.1) — 12KB
• img148377401_0.jpg (GRAPHIC) — 8KB
• 0000950170-24-108126.txt ( ) — 180KB
• pepg-20240919.xsd (EX-101.SCH) — 25KB
• pepg-20240919_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 19, 2024, the Company issued a press release announcing the foregoing. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit Number Description 99.1 Press release issued by PepGen Inc. on September 19, 2024 104 Cover Page Interactive Data Filed (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PEPGEN INC. Date: September 19, 2024 By: /s/ Noel Donnelly Noel Donnelly, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR